Phase III Study of Interferon Alfa-NL as Adjuvant Treatment for Resectable Renal Cell Carcinoma: An Eastern Cooperative Oncology Group/Intergroup Trial

Messing, Edward M.; Manola, Judith; Wilding, George; Propert, Kathleen J.; Fleischmann, Jonathan; Crawford, E. David; Pontes, J. Edson; Hahn, Richard G.; Trump, Donald L.

doi:10.1200/jco.2003.02.005

Cited by 282 publications

(159 citation statements)

References 35 publications

Supporting

Mentioning

147

Contrasting

Unclassified

Order By: Relevance

“…In recent years, molecular targeted therapies have been developed and have shown significant objective responses (1-3), and they have been incorporated into current standard therapies of metastatic RCC; however, these molecular targeted therapies have not provided durable responses. RCC is regarded as an immunogenic malignancy and has well-documented responses to some cytokines such as interleukin-2 (IL-2) and IFN-a, and some patients have shown significant responses to treatments with these cytokines (4)(5)(6). However, the results have been limited by such nonspecific immunotherapy; therefore, cancer-specific immunotherapy may become a new modality for patients with metastatic RCC.…”

Section: Introductionmentioning

confidence: 99%

HSP DNAJB8 Controls Tumor-Initiating Ability in Renal Cancer Stem–like Cells

et al. 2012

View full text Add to dashboard Cite

Cancer stem-like cells (CSC) are a small population of cancer cells with superior tumor initiating, self-renewal, and differentiation properties. In this study, we show that the cancer-testis antigen and HSP40 family member DNAJB8 contributes to the CSC phenotype in renal cell carcinoma (RCC). DNAJB8 overexpression increased the percentage of side population (SP) cells representing CSCs in RCC cells, enhancing their tumor-initiating ability. Conversely, attenuation of DNAJB8 decreased SP cells and reduced tumor-initiating ability. The utility of DNAJB8 as an immunologic target was established in DNA vaccination experiments. Compared with immunization with the tumor-associated antigen survivin, which was expressed in both CSCs and non-CSCs in RCC, immunization with Dnajb8 expression plasmids yielded stronger antitumor effects. Together, our findings suggest that DNAJB8 plays a role in CSC maintenance and that it offers a candidate for CSC-targeting immunotherapy in RCC.

show abstract

Section: Introductionmentioning

confidence: 99%

HSP DNAJB8 Controls Tumor-Initiating Ability in Renal Cancer Stem–like Cells

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Survival benefits have been achieved with radical nephrectomy, or in select cases, nephron-sparing surgery. Following complete surgical resection, there has been no proven disease-free survival or overall survival benefit with the use of adjuvant immunotherapy [1]. Attempts to combine chemotherapy with immunotherapy have been unsuccessful in improving disease free survival and actually appear to be detrimental to overall survival [2].…”

Section: Introductionmentioning

confidence: 99%

Localized Palmar–Plantar Epidermal Hyperplasia: A Previously Undefined Dermatologic Toxicity to Sorafenib

et al. 2007

View full text Add to dashboard Cite

The development of multitargeted tyrosine kinase inhibitors has provided significant advances in the treatment of renal cell carcinoma. This case describes initial therapy for managing renal cell cancer with the administration of sorafenib, a multitargeted tyrosine kinase inhibitor. We report the development of localized palmar-plantar epidermal hyperplasia, a rare but significant cutaneous adverse event from sorafenib therapy.Mild-to-moderate dermatologic toxicity from sorafenib has been well described in the literature. We also review the current knowledge and the proposed hypothesis for the development of cutaneous events related to tyrosine kinase inhibitors. This particular case represents a unique form of dermatologic toxicity to sorafenib that has not previously been described in the literature. The Oncologist

show abstract

“…Le traitement adjuvant avec des cytokines n'améliore pas la survie globale après la néphrectomie 8 . Les résultats de plusieurs essais cliniques avec les agents antiangiogéniques adjuvants (ITK du VEGFr, anticorps anti-VEGF ou inhibiteurs de mTOR) ne seront pas publiés avant plusieurs années.…”

Section: Traitement Adjuvantunclassified

Prise en charge du cancer du rein de stade avancé : Mise à jour 2013 des lignes directrices consensuelles du Forum canadien sur le cancer du rein

North¹

2013

CUAJ

View full text Add to dashboard Cite

Phase III Study of Interferon Alfa-NL as Adjuvant Treatment for Resectable Renal Cell Carcinoma: An Eastern Cooperative Oncology Group/Intergroup Trial

Abstract: Adjuvant treatment with interferon did not contribute to survival or relapse-free survival in this group of patients.

Cited by 282 publications

References 35 publications

HSP DNAJB8 Controls Tumor-Initiating Ability in Renal Cancer Stem–like Cells

HSP DNAJB8 Controls Tumor-Initiating Ability in Renal Cancer Stem–like Cells

Localized Palmar–Plantar Epidermal Hyperplasia: A Previously Undefined Dermatologic Toxicity to Sorafenib

Prise en charge du cancer du rein de stade avancé : Mise à jour 2013 des lignes directrices consensuelles du Forum canadien sur le cancer du rein

Contact Info

Product

Resources

About